| DCAPI1512 |
Lapatinib
Featured
|
Lapatinib |
|
| DC3143 |
Lapatinib ditosylate
Featured
|
Lapatinib Ditosylate (GW572016, GW2016, Tykerb, Tyverb) is a potent EGFR and ErbB2 inhibitor with IC50 of 10.8 and 9.2 nM, respectively. |
|
| DC9433 |
Lapatinib (ditosylate) |
Lapatinib ditosylate(GW-572016 ditosylate) is a potent EGFR and ErbB2 inhibitor with IC50 of 10.8 and 9.2 nM, respectively.
|
|
| DC10755 |
LSZ-102
Featured
|
LSZ102 is a potent, orally bioavailable Selective Estrogen Receptor Degrader (SERD) for the Treatment of Estrogen Receptor Positive Breast Cancer. |
|
| DC10987 |
LTX-315 |
This product is discontinued. LTX-315 (Oncopore) is a synthetic 9-mer anticancer peptide that preferentially permeabilizes mitochondrial membranes, thereby causing partially BAX/BAK1-regulated, caspase-independent necrosis. |
|
| DC9836 |
Mivebresib(ABBV-075）
Featured
|
Mivebresib is a novel BET family inhibitor, disrupts critical transcription programs that drive prostate cancer growth to induce potent anti-tumor activity in vitro and in vivo. |
|
| DC7211 |
Neratinib (HKI-272)
Featured
|
Neratinib (HKI-272) is an orally available, irreversible tyrosine kinase inhibitor with IC50 of 59 nM and 92 nM for HER2 and EGFR, respectively. |
|
| DC8021 |
Indoximod (NLG-8189)
Featured
|
NLG-8189 is an inhibitor of IDO and INDOL1 (IDO2) |
|
| DC9936 |
NMS-P118
Featured
|
NMS-P118 is a potent, orally available, and highly selective PARP-1 inhibitor with excellent ADME and pharmacokinetic profiles and high efficacy in vivo. |
|
| DC4118 |
NVP-BEP800
Featured
|
NVP-BEP800 is a novel, fully synthetic HSP90β inhibitor with IC50 of 58 nM. |
|
| DC8248 |
Ostarine(MK-2286)
Featured
|
Ostarine (MK-2866) is a selective androgen receptor modulator (SARMs) that regulates cardiomyocyte function, improves bone healing, regulates uterine function, and influences muscle tissue metabolism. |
|
| DC8469 |
Palbociclib
Featured
|
Palbociclib (PD-0332991) is an orally available pyridopyrimidine-derived cyclin-dependent kinase (CDK) inhibitor with potential antineoplastic activity. |
|
| DC5067 |
Palbociclib (PD0332991 HCl)
Featured
|
Palbociclib is an oral, small molecule cyclin-dependent kinase 4/6 (CDK4/6) inhibitor, now in Phase 3 clinical development for advanced breast cancer. |
|
| DC7704 |
Poziotinib
Featured
|
Poziotinib, is an orally bioavailable, quinazoline-based pan epidermal growth factor receptor (EGFR or HER) inhibitor with potential antineoplastic activity. |
|
| DC7276 |
Saracatinib (AZD0530)
Featured
|
Saracatinib (AZD0530) is a potent Src inhibitor with IC50 of 2.7 nM, and potent to c-Yes, Fyn, Lyn, Blk, Fgr and Lck; less active for Abl and EGFR (L858R and L861Q). |
|
| DC8049 |
SNG-1153
Featured
|
SNG-1153 is a synthetic modulator of ER-α36 |
|
| DC7302 |
SU14813
Featured
|
SU14813 is an oral, multitargeted tyrosine kinase inhibitor (TKI) targeting vascular endothelial growth factor receptors (VEGFR), platelet-derived growth factor receptors (PDGFR), Kit, and fms-like tyrosine kinase 3 (FLT-3). |
|
| DC9311 |
Serabelisib(TAK-117,INK1117,MLN1117)
Featured
|
TAK-117(INK1117,MLN1117) is an orally bioavailable inhibitor of the class I phosphoinositide 3-kinase (PI3K) alpha isoform with potential antineoplastic activity. |
|
| DC1102 |
Tariquidar (XR9576)
Featured
|
Tariquidar (XR9576) is a potent and selective noncompetitive inhibitor of P-glycoprotein with Kd of 5.1 nM. |
|
| DC8899 |
ABT888 (free base)
Featured
|
Veliparib (ABT-888) is a potent inhibitor of PARP1 and PARP2 with Ki of 5.2 nM and 2.9 nM, respectively. |
|
| DC5150 |
Veliparib (ABT-888 hydrochloride)
Featured
|
Veliparib is a potent inhibitor of both PARP-1 and PARP-2 by [3H]NAD+ with Kis of 5.2 and 2.9 nmol/L, respectively. |
|
| DC9514 |
Deforolimus
Featured
|
Deforolimus(AP23573; MK-8669; Ridaforolimus) is a selective mTOR inhibitor with IC50 of 0.2 nM; while not classified as a prodrug, mTOR inhibition and FKBP12 binding is similar to rapamycin.
IC50 value: 0.2 nM [1]
Target: mTOR
in vitro: Treatment of HT |
|
